- Q1 2024 Relmada Therapeutics Inc Earnings Call TranscriptMay 08, 2024€3.54Earnings
- Q4 2023 Relmada Therapeutics Inc Earnings Call TranscriptMar 19, 2024€4.98 (-1.39%)Earnings
- Q3 2023 Relmada Therapeutics Inc Earnings Call TranscriptNov 08, 2023€2.78 (-4.79%)Earnings
- Q2 2023 Relmada Therapeutics Inc Earnings Call TranscriptAug 08, 2023€2.36 (+4.42%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Relmada Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Q1 2023 Relmada Therapeutics Inc Earnings Call TranscriptMay 11, 2023€2.94 (-2.65%)Earnings
- Q4 2022 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2023€2.16 (-5.26%)Earnings
- Relmada Therapeutics Inc Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder - Corporate Call TranscriptDec 07, 2022
- Q3 2022 Relmada Therapeutics Inc Earnings Call TranscriptNov 10, 2022€5.9Earnings
- Q2 2022 Relmada Therapeutics Inc Earnings Call TranscriptAug 11, 2022€28 (+6.06%)Earnings
- Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Q1 2022 Relmada Therapeutics Inc Earnings Call TranscriptMay 05, 2022€22.6 (-3.42%)Earnings
- Q4 2021 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2022€21.2 (+8.72%)Earnings
- Relmada Therapeutics Inc Results of Human Abuse Potential Study of REL-1017 vs. Ketamine - Corporate Call TranscriptFeb 23, 2022
- Q3 2021 Relmada Therapeutics Inc Earnings Call TranscriptNov 11, 2021€21.4Earnings
- Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Relmada Therapeutics Inc Earnings Call TranscriptAug 10, 2021€19 (-3.55%)Earnings
- Relmada Therapeutics Inc REL-1017 Clinical Data Update Call TranscriptJul 27, 2021
- Q1 2021 Relmada Therapeutics Inc Earnings Call TranscriptMay 12, 2021€28.2Earnings
- Q4 2020 Relmada Therapeutics Inc Earnings Call TranscriptMar 23, 2021€29 (+0.17%)Earnings
Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. This is Rahul Sood here from Morgan Stanley Healthcare Investment Banking. We are joined today by Sergio Traversa, Chief Executive Officer of Relmada. Very honored and very pleased to have you join us, Sergio.
Before I turn it over to you, I would like to remind of 2 things to the audience here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
The second housekeeping item is we will be asking the audience to submit their questions through the question portal. I see there are a few that are coming in already. We'll use this time, Sergio, to, a, have you walk through the high -- the key points about the company, what's happening at the moment and the -- and any upcoming data points that you would ask the investors to focus on. And then we can get into some of the more fireside Q&A format after that.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)